Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13861855 | 0.90 | BRD4 (0.31) | PARP1KCNH2 | |
| SCHEMBL13548258 | 0.86 | PARP1 (0.37) | PARP1PDE4B | |
| SCHEMBL12345221 | 0.82 | PARP1 (0.39) | PARP1PDE4B | |
| SCHEMBL13547875 | 0.81 | PARP1 (0.36) | PARP1PDE4BKCNH2 | |
| SCHEMBL8363222 | 0.80 | HTR2A (0.36) | PARP1PDE4BCYP2A6KDM4E | |
| SCHEMBL18509002 | 0.79 | TRPA1 (0.38) | PARP1CYP2A6KDM4E | |
| SCHEMBL26462276 | 0.76 | PTGS2 (0.47) | CYP2A6 | |
| SCHEMBL30542231 | 0.76 | PTGS2 (0.47) | CYP2A6 | |
| SCHEMBL23714719 | 0.76 | PARP1 (0.42) | PARP1CYP2A6 | |
| SCHEMBL12078457 | 0.75 | PARP1 (0.58) | PARP1PDE4BCYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2104670-B3 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABA-B RECEPTOR MODULATORS | ADDEX PHARMACEUTICALS SA (CH) | 2016-09-21 | — | — | EP | disclosed |
| EP-2104670-B1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABA-B RECEPTOR MODULATORS | ADDEX PHARMACEUTICALS SA (CH) | 2016-02-17 | — | — | EP | disclosed |
| US-20140371223-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | ADDEX PHARMA S.A. (CH) | 2014-12-18 | — | — | US | disclosed |
| US-8779129-B2 | Triazinedione derivatives as GABAB receptor modulators | ADDEX PHARMA S.A. (CH) | 2014-07-15 | — | — | US | disclosed |
| EP-2662366-A1 | Novel triazinedione derivatives as GABA-B receptor modulators | ADDEX Pharma S.A. (CH) | 2013-11-13 | — | — | EP | disclosed |
| US-20130123262-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | ADDEX PHARMA S.A. (CH) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371223-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | CHRNA5, GABRA5, GABRB3 | PARP1 3835/4885PDE4B 279/4885CYP2A6 1652/4885 |
| US-20130123262-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | CHRNA5, GABRA5, GABRB3 | PARP1 3835/4885PDE4B 279/4885CYP2A6 1652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.